Nov. 12, 2014 — Catalist-listed QT Vascular Ltd. has acquired a novel technology platform called Java, and all associated intellectual property, which was developed independently in Israel.
The first product in the Java product line is an aortic valvuloplasty balloon for use as a pre-dilatation device prior to a TAVR (Transcatheter Valve Replacement) procedure or a stand-alone treatment in select patients where TAVR is not appropriate. It is designed to be a highly deliverable, puncture resistant device that has proprietary tines which aid in stability and reduce the need for peri-procedural cardiac pacing. Minimally invasive angioplasty is the core expertise of QT Vascular today, and the Java aortic valvuloplasty balloon is a natural extension of the Group's technology offering to a new therapeutic indication.
The acquisition of this novel technology platform is in line with QT Vascular's efforts to grow its new product pipeline in recent months. The acquisition of this technology is not expected to have a material financial impact on the Group's earnings per share and net tangible assets per share for the current financial year ending 31 December 2014.On15 September 2014, QT Vascular announced that it has enrolled the first European patient in the ENDURE Trial inGermany. Patients' enrollment in Germany and New Zealand is progressing rapidly and is consistent with the group's expectations. The Group previously announced that it has applied for CE marking approval with respect to the ChocolateTouch, its advanced drug coated peripheral balloon.
QT Vascular also disclosed that its wholly owned US subsidiary, TriReme Medical LLC, received notification from the United States Food and Drug Administration (FDA) of 510(K) clearance to market the Chocolate Percutaneous Transluminal Coronary Angioplasty Balloon Catheter ("Chocolate PTCA") in the United States.
For more information: www.qtvascular.com
June 13, 2024 
